Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Krystal Biotech reports robust Q3 earnings and eyes global expansion

Krystal Biotech's Q3 performance showcased positive earnings and high patient conversion rates.
Despite challenges in patient source diversity and conversion cycle, the company remains well-positioned.
Opportunities lie in global expansion, pipeline advancement, and leadership enhancements.
Overall, Krystal Biotech's strong financials and patient compliance bode well for future growth.

Krystal Biotech excels with VYJUVEK, eyes global expansion

Krystal Biotech's VYJUVEK shows strong performance and market potential
Balanced financials and strategic clinical trials position for future growth
Challenges include competitive landscape shifts and global expansion execution
Opportunities lie in market expansion, pipeline advancements, and partnerships

Krystal Biotech excels in Q1 2024, eyes global expansion

Krystal Biotech's strong performance in Q1 2024 reflects continued growth and execution.
The company's focus on compliance, pipeline advancements, and global expansion positions it well.
Challenges in conversion time and reimbursement delays require strategic mitigation.
Opportunities in European and Japanese markets, patient education, and new product data.

Krystal Biotech excels in Q2 2024, eyes global expansion

Krystal Biotech's Q2 2024 performance reflects strong revenue growth, profitability, and operational efficiency, positioning the company well for future success.
The company's focus on patient demand, compliance, and global expansion highlights its strategic priorities and growth trajectory.
While facing challenges in manufacturing expansion and clinical data readouts, Krystal Biotech has opportunities to drive revenue growth and market expansion through strategic initiatives.

Krystal Biotech excels in Q3 with VYJUVEK success and global expansion plans

Krystal Biotech's Q3 performance reflects strong revenue growth, profitability, and strategic advancements in product development and market access.
While facing challenges related to compliance, market dynamics, and competitive landscape, the company is well-positioned for international expansion and future growth.
By capitalizing on strengths in commercial strategies, pipeline progress, and revenue diversification, Krystal Biotech can navigate challenges and seize opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today initial clinical results from its ongoing KYANITE-1 study evaluating inhaled KB707 in patients with solid tumors of the lung. KB707 administered via inhalation demonstrated early evidence of monotherapy activity that was most pronounced in patients with advanced non-small cell lung cancer (NSCLC), where an objective response rate (ORR) of 27% and disease control rate (DCR) of 73% were observed as of data cut-off on December 6, 2024.

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) cancelled the Oral Explanation regarding the Company's Marketing Authorization Application for beremagene geperpavec-svdt (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) that was scheduled for December 6, 2024, and asked the Company to submit written responses to the remaining outstanding issues.

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:

Krystal Biotech to Present at Upcoming Investor Conferences

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Stéphane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Yigal Nochomovitz - Citigroup Ritu Baral - TD Cowen Sami Corwin - William Blair Gavin Clark-Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Andrea Newkirk - Goldman Sachs Operator Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to loss of $0.67 per share a year ago.

Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy

The company anticipates significant Q4 2024 data releases for KB707 in solid tumors and KB408 in AATD lung disease, potentially boosting shareholder value. Jeune Therapeutics, a subsidiary, shows promise in aesthetics with positive phase 1 data, changing the treatment paradigm in the aesthetics market space. VYJUVEK, approved for DEB, saw a 55.3% revenue increase in Q2 2024, with potential European expansion pending MAA approval.

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Krystal Biotech has gained 256% on average every year since its IPO.

Biotech Stock Offers A Buy Point After 256% Average Yearly Gain

PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the 2024 Cantor Global Healthcare Conference on September 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:20 pm ET and host investor meetings throughout the day.

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a company presentation at 12:30 pm ET and host investor meetings throughout the day.

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock

KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - Senior Vice President, Patient Access, Analytics and Operations Christine Wilson - Senior Vice President and Head, U.S. Sales and Marketing Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Ritu Baral - TD Cowen Andrea Tan - Goldman Sachs John Boyle - William Blair Yigal Nochomovitz - Citi Gavin Clark Gartner - Evercore ISI Dae Gon Ha - Stifel Debjit Chattopadhyay - Guggenheim Securities Operator Thank you for standing by. And welcome to Krystal Biotech's Second-Quarter 2024 Earnings Conference Call.

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

Amalgamated Financial Corp

KRYS and AMAL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2024.

Best Momentum Stock to Buy for August 8th

Driven Brands Holdings

Meritage Homes

Royal Caribbean Cruises

UL Solutions Inc

MTH, ULS, KRYS, RCL and DRVN have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2024.

New Strong Buy Stocks for August 8th

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Krystal Biotech (KRYS) Upgraded to Buy: What Does It Mean for the Stock?

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to loss of $1.25 per share a year ago.

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates

Krystal Biotech shares have rocketed 65% this year, driven by the company's star product, a gene therapy for a rare skin disease.

News for Krystal Biotech Stock (KRYS)